Abstract
BackgroundCheckpoint inhibitors have demonstrated clinical benefit for several types of cancer, but still a large proportion of patients do not respond to treatment. To improve response rates, many combination therapies...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
